Answers are grounded in this paper and cite their sources.
For the past 20 years, Cambridge Healthtech Institute (CHI) has organized an international conference called Molecular Med Tri-Con. This year, the week-long meeting was held in San Francisco in mid-February. The event brings together over 3,000 participants, including C-suite executives, Ph.D scientists, directors and managers from leading Biotech and Pharma Organizations and physicians. Over 140 exhibitors were crammed into the Moscone North conference center. It would be hard to find a conference with so many tracks and individual speakers focused on the molecular medicine. This year’s meeting had 12 different tracks and 20 core programs encompassing diagnostics, therapeutics, clinical trials and sequencing, informatics and cancer. For many participants, the program offers an opportunity for leading researchers, business executives, investors and scientists to network and engage. The emphasis is clearly on industry and the business of cancer. Most of the vendors were in the life sciences space and there was only one digital pathology (DP) vendor. If you were entrepreneurial, intent on getting your business started and wanted to meet up with like-minded individuals, this conference would be a good place to start. The authors were speakers at the DP track, part of the diagnostics channel that included molecular diagnostics, personalized diagnostics, cancer molecular markers, circulating tumor cells and companion diagnostics. The talks were a mixture of big data, molecular and DP experiences, including workflow, quality, education, analytics and new applications. For example, Richard Levinson talked about multiplexed image analysis in the context of the tumor-stromal interaction and the complex molecular data that needs to be integrated into our considerations. Anil Parwani expounded the needful considerations in validation of whole slides for clinical use. Keith Kaplan reviewed the current regulatory landscape and offered perspective on what we do and don’t know is going on inside the Food and Drug Administration (FDA). Sushmitha Muhkerjee presented some fascinating data on multiphoton microscopy and optical tomography with hints of future tools applying these and other techniques. David Wilbur and Jian Yu Rao shared experiences in establishing and using DP in a consultative framework, noting the common pitfalls and potential benefits of such structures while Sara Grimmsgaard explained in her presentation how this has been successfully implemented in a large Veterans Administration region. Dirk Vossen explained the intricacies of fixed and flexible image registration making it evident how these tools will enhance (and hopefully not hinder) diagnostic acumen. Elizabeth Krupinski used data from her experience in Arizona to demonstrate how digital slides and related eye-tracking tools could be used to provide diagnostic quality control as well as enhance the learning experience for trainees. We found these and the other talks interesting and at times cutting edge. Generally, Pathologists have not played much of a role in this event for a variety of reasons, so when the organizers chose to add a track in the meeting schedule for DP, one might well ask, “Why should a Pathologist care what they do? (or bother to attend).” It is a legitimate question and raises a host of other questions about the state of the field of DP today and what lies on down the road. Looking over the slate of invited speakers, the majority of whom were leaders in the field of pathology and DP in particular, one could have anticipated a quality experience. In reflecting on our participation in the CHI Molecular Medicine Tri-Con, we would like to offer our perspective on the answers to some of these questions as illuminated by many of the presentations in that setting.
No takes yet. Share an insight, caveat, or question.
Hassell et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: